Folger Nolan Fleming Douglas Capital Management Inc. Has $14.99 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Folger Nolan Fleming Douglas Capital Management Inc. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,659 shares of the company's stock after selling 2,130 shares during the quarter. Johnson & Johnson makes up 1.6% of Folger Nolan Fleming Douglas Capital Management Inc.'s portfolio, making the stock its 16th largest position. Folger Nolan Fleming Douglas Capital Management Inc.'s holdings in Johnson & Johnson were worth $14,991,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. IFS Advisors LLC boosted its position in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson in the third quarter valued at $35,000. Mowery & Schoenfeld Wealth Management LLC increased its holdings in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after buying an additional 91 shares during the last quarter. Finally, Activest Wealth Management bought a new stake in Johnson & Johnson during the third quarter worth $40,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE JNJ traded down $0.74 during trading on Monday, reaching $147.03. The company's stock had a trading volume of 10,678,393 shares, compared to its average volume of 6,880,262. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The firm has a 50 day moving average price of $148.51 and a 200 day moving average price of $156.10. The firm has a market capitalization of $353.99 billion, a price-to-earnings ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is currently 71.78%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent analyst reports. StockNews.com lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday. Morgan Stanley boosted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 16th. Wells Fargo & Company raised their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 16th. Royal Bank of Canada boosted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a report on Wednesday, October 16th. Finally, Guggenheim raised their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a report on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $174.29.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the firm's stock in a transaction on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.